2 This beneficial effect is thought to be mediated, in part, by activation of hydroxy-carboxylic acid receptor 2 (HCA2) expressed in adipocytes, causing a drop in the intracellular cAMP level and inhibition of lipolysis.
N icotinic acid (also commonly called niacin or vitamin B3) is a water-soluble small molecule that is converted in vivo to nicotinamide adenine dinucleotide, a coenzyme involved in the catabolism of fat. As one of the oldest lipid-lowering medications, 1 nicotinic acid has been prescribed for >50 years. At a daily dosage of gram quantities, nicotinic acid (but not its derivative nicotinamide) lowers the serum concentrations of total cholesterol and low-density lipoprotein, whereas raises that of high-density lipoprotein, reducing the risk of mortality from cardiovascular disease.
To take advantage of the beneficial effects of nicotinic acid fully and to reduce the drop-off rate, a better understanding of the molecular events underlying flushing and potential treatments is of great practical importance. Interestingly, recent studies discovered that pharmacological blockade of cyclooxygenase (by aspirin) and prostaglandin D2 receptor 1 (by laropiprant) does not fully inhibit flushing. 13, 14 Meanwhile, research in both humans and animal models showed that nicotinic acid-induced flushing is a biphasic process. 15, 16 These findings, together with the selective tachyphylaxis behavior, indicate that flushing may be mediated by target(s) outside the beneficial HCA2 pathway, raising hope that flushing can be inhibited while preserving the clinic efficacy of nicotinic acid.
Intriguingly, capsaicin (the active compound of spicy chili peppers) also causes flushing symptoms closely resembling that caused by nicotinic acid. 17 The capsaicin receptor TRPV1 is a heat-sensing ion channel that responds to many physical and chemical stimuli. [18] [19] [20] The activation of TRPV1 causes hot and pain sensations and thermoregulatory responses, such as sweating and vasodilation. 21 Noticeably, Langerhans cells and keratinocytes, the critical carriers of flushing reaction, respond to nicotinic acid with an increase in intracellular Ca 2+ , 22, 23 whereas TRPV1 is a nonselective Ca 2+ -permeable cation channel richly expressed in keratinocytes and Langerhans cells. 24, 25 Furthermore, repetitive administration of capsaicin results in tachyphylaxis, similar to that seen with nicotinic acid. 26 Taken together, these findings point to the possibility that TRPV1 may play a role in nicotinic acid-induced flushing. We were further drawn to this possibility by observations that a TRPV1-specific antagonist, AMG9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b] [1, 4] dioxin-6-yl)acrylamide], can selectively inhibit the early phase of nicotinic acid-induced flushing response (Schaefer et al, unpublished data). Hence, in the present study, we tested TRPV1 for nicotinic acid response.
Material and Methods
Materials and Methods are available in the online-only Supplement.
Results

Trpv1
-/-Knockout Mice Exhibited Much Reduced Response to Nicotinic Acid
To develop an animal model of nicotinic acid-induced vasodilation, we used laser Doppler perfusion imaging to examine the cutaneous perfusion increase (vasodilation) in mouse. Nicotinic acid (dissolved in physiological saline, pH 7.4) was administered subcutaneously to anesthetized mice at a dosage of 120 mg/kg. Change in the ear blood flow was measured with a laser Doppler flowmeter. As shown in Figure 1 , wild-type mice responded to nicotinic acid treatment with a substantial increase in blood flow, 27 which is similar to the nicotinic acid-induced flushing in humans. 28, 29 Noticeably, the nicotinic acid response was substantially reduced in Trpv1 -/-mice. In addition, neither wild-type nor knockout mice exhibited detectable response to vehicle treatment. These observations are fully consistent with the hypothesis that TRPV1 serves as a target for nicotinic acid.
Nicotinic Acid Directly and Potently Activates TRPV1
The molecular structure of nicotinic acid loosely resembles the head-group of capsaicin (Figure 2A ). To test whether nicotinic acid acts as a TRPV1 agonist, we first conducted patchclamp recordings in either the cell-attached or the whole-cell configuration from mouse TRPV1 (mTRPV1)-expressing HEK293 cells. When applied from the extracellular side, no channel activation was observed acutely (Figure 2B, left) . However, when applied to the intracellular side of inside-out patches, nicotinic acid strongly potentiated the channel, eliciting large currents at room temperature ( Figure 2B , right). We measured the dose-response relationship for nicotinic acid, which yielded an estimated half maximal effective concentration (EC 50 ) value of 62.34±0.75 mmol/L (n=4; Figure 2C ). Because the EC 50 value for capsaicin under the same conditions was 157.71±16.87 nmol/L (n=4), nicotinic acid is a much less potent agonist for TRPV1. The Hill coefficient of nicotinic acid response was estimated to be 2.87±0.09 (n=4), suggesting the binding of ≥3 nicotinic acid molecules that promote channel activation with positive cooperativity ( Figure 2C ).
Although the apparent binding affinity for nicotinic acid is low, we found surprisingly that its efficacy is even higher than capsaicin. At 130 mmol/L, nicotinic acid elicited a current ≈35% higher than 10 μmol/L capsaicin (a saturating concentration; Figure 2D and 2E). Given that capsaicin at saturating concentrations activates TRPV1 to an open probability of ≈80%, the observation indicates that the larger current elicited by nicotinic acid could not simply be because of a higher maximum open probability; instead, there has to be an increase in single-channel conductance or both open probability and conductance. Single-channel recordings confirmed that indeed nicotinic acid activates TRPV1 dose dependently, reaching a high open probability at 130 mmol/L ( Figure 2F ). In addition, although the single-channel conductance at most nicotinic acid concentrations was similar to that of capsaicin-induced currents, at 130 mmol/L the conductance increased significantly ( Figure 2F and 2G) . Correction for the change in single-channel conductance slightly shifted the dose-response curve ( Figure 2C ). Because the concentration required to exhibit a permeation effect was much higher than that for gating, nicotinic acid must bind to a distinct site (or sites, most likely close to the pore) to affect conductance.
In summary, our results confirmed that nicotinic acid dose dependently activates TRPV1. When compared with capsaicin, nicotinic acid exhibits a much lower apparent affinity but higher efficacy because of a combination of gating (higher open probability) and permeation (higher conductance) effects.
Human TRPV1 Exhibits High Nicotinic Acid Sensitivity
TRPV1 channels from different species exhibit distinct properties. 20, 30, 31 To make sure that knockout mice and the mTRPV1 channel are suitable models for the study of nicotinic acid effects in humans, we repeated patch recordings from cells expressing human TRPV1 (hTRPV1) channels. We found that nicotinic acid could also potently activate hTRPV1 from the intracellular side ( Figure 3A) . Most properties tested, for example, the relative amplitudes between capsaicin and nicotinic acid-induced currents, were similar to those of mTRPV1. To test the sensitivity of hTRPV1 to nicotinic acid, the 0.13 mmol/L concentration (a clinically attainable concentration in the plasma during niacin treatment) was used, whereas the recording temperature was raised to 37°C (near-normal human body temperature). We found that indeed even at this low concentration, nicotinic acid could already activate hTRPV1 when the recording temperature was higher than the room temperature; at 37°C, robust currents were observed ( Figure 3B ). As expected, in the absence of nicotinic acid, hTRPV1 was not activated at 37°C but could be heat activated at higher temperatures (38.92±0.68°C; n=12; Figure 3C ). In the presence of 0.13 mmol/L nicotinic acid, the channel started to be heat activated at significantly lower temperatures (24.88±0.86°C; n=4; P<0.001; Figure 3C and 3D). Because we did not observe detectable activity from the mTRPV1 at this concentration even at 37°C (data not shown), it seems that the hTRPV1 is more sensitive to nicotinic acid. However, because hTRPV1 current in inside-out patches inactivated rapidly ( Figure 3A ), biophysical analyses were performed using the mTRPV1.
Nicotinic Acid and Capsaicin Activate TRPV1 Synergistically
TRPV1 is a well-known molecular integrator of many chemical and physical stimuli that elicit pain. To understand how nicotinic acid, a new TRPV1 agonist, interacts with the channel, we first investigated the relationship between nicotinic acid and capsaicin. We observed that a combined application of low concentrations of nicotinic acid and capsaicin potentiated TRPV1 to a greater extent than either of them applied independently ( Figure 4A ). Because of this synergistic effect, 65 mmol/L nicotinic acid (a near-EC 50 concentration) leftshifted the capsaicin dose-response curve appreciably, reducing the EC 50 value for capsaicin by about one-half (from 157.71±16.87 to 81.04±16.4 nmol/L; P<0.05; Figure 4B ). This change makes capsaicin a more potent agonist in the presence of nicotinic acid. Interestingly, the Hill coefficient was also doubled in the presence of nicotinic acid, indicating that nicotinic acid promotes the cooperativity of capsaicininduced activation gating.
Conversely, capsaicin at 200 nmol/L (a near-EC 50 concentration) also shifted the nicotinic acid dose-response curve to the left, reducing its EC 50 value by ≈50% ( Figure 4C ). This was achieved without a statistically significant change in the Hill coefficient value. In summary, nicotinic acid and capsaicin mutually potentiate each other in activating TRPV1.
Nicotinic Acid and Capsaicin Bind to Different Channel Sites
To test whether nicotinic acid binds to the same binding site for capsaicin, which is located at a pocket formed by S2-S3 linker, S3, S4, S4-S5 linker, S5 and S6, 31, 32 we used a TRPV1 antagonist, capsazepine ( Figure 4D, top) . As a capsaicin analog, capsazepine is known to compete for the same binding sites in TRPV1; however, being an antagonist, binding of capsazepine inhibits TRPV1 activity induced by capsaicin with a half maximal inhibitory concentration (IC 50 ) of 420 nmol/L, 33 whereas inhibits nicotinic acid-induced TRPV1 currents with an IC 50 of 2.42±0.66 μmol/L (n=3; Figure 4D , bottom). As expected, we observed that capsazepine at 30 μmol/L (a saturating concentration) almost completely inhibited capsaicin-evoked currents ( Figure 4E and 4F, top) . However, at this high concentration, capsazepine could only partially block channel activation triggered by 130 mmol/L nicotinic acid ( Figure 4E and 4F, bottom) . As a control, 20 mmol/L intracellular Ba 2+ (a pore blocker) 34 fully inhibited TRPV1 currents induced by either capsaicin or nicotinic acid ( Figure 4E and 4F) . These results confirmed that nicotinic acid and capsaicin bind to distinct sites in TRPV1.
Nicotinic Acid and 2-Aminoethoxydiphenyl Borate Also Activate TRPV1 Synergistically 2-Aminoethoxydiphenyl borate (2-APB; Figure 5A , top) is a common activator for TRPV1, TRPV2, and TRPV3 channels. 35 For TRPV1, 2-APB exhibited an EC 50 value of 157.2±17.9 μmol/L (n=4), making 1 mmol/L a saturating concentration ( Figure 5C ). We observed that nicotinic acid and 2-APB also exhibited synergistic effects in promoting TRPV1 activation. The current amplitude induced by 180 μmol/L 2-APB was significantly increased in the presence of Figure 5A, bottom) . Coapplication of 65 mmol/L nicotinic acid also further promoted open probability of the channel activated by 2-APB at saturating concentration ( Figure 5B ). As further evidence of synergistic effects, 65 mmol/L nicotinic acid left-shifted the 2-APB dose-response curve without changing the Hill slope factor ( Figure 5C ), whereas 180 μmol/L 2-APB not only left-shifted the nicotinic acid dose-response curve but also significantly reduced the Hill slope factor ( Figure 5D ).
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Nicotinic Acid Promotes Voltage-and Heat-Dependent TRPV1 Activation
Results described above demonstrated that nicotinic acid both directly activates TRPV1 and facilitates channel activation by other agonists. Because TRPV1 is a polymodal sensor for both chemical and physical stimuli, to understand how nicotinic acid promotes TRPV1 activity under physiological conditions fully, we investigated effects of nicotinic acid on voltage-and heat-dependent channel activation. As shown in Figure 6A , voltage-dependent activation was clearly boosted in the presence of 65 mmol/L nicotinic acid. As a result, there is a significant left-shift of the G-V curve, with half-activation voltage changing from 150.9±5.34 to 70.21±6.55 mV ( Figure 6B ). This shift would not only make depolarization more effective in activating TRPV1 but also confer a higher open probability at the resting membrane potential (-20 to -30 mV in keratinocytes; comparing with -60 to -70 mV in neurons). 36, 37 However, it seems that at clinically attainable concentrations, nicotinic acid cannot appreciably activate TRPV1 by shifting voltage-dependent activation toward the resting membrane potential range.
Importantly, we found that nicotinic acid can strongly affect the heat activation of TRPV1, as demonstrated by results shown in Figure 3 . Gating of TRPV1 is strongly temperature dependent. The sharply defined temperature activation threshold is characteristic of the channel and can be modulated by factors such as chemical ligands and the phosphorylation state of the channel. 20 This plasticity potentially confers a broader range of temperature sensitivity on TRPV1-expressing cells. We observed that, similar to other TRPV1 activators such as capsaicin, proton and Mg at clinically attainable concentrations, nicotinic acid will cause a substantial fraction of TRPV1 channel to be heat activated. Combining this strong sensitization effect on heat activation with potentiation effects on other activators, it is conceivable that nicotinic acid can substantially activate TRPV1 in vivo, leading to the flushing response.
Nicotinic Acid Activates TRPV1 From the Intracellular Side
Our data showed that nicotinic acid only activates TRPV1 from the intracellular side but not from the extracellular side ( Figures 2B and 7A ). This observation raised an important question, that is, could nicotinic acid from extracellular sources (blood supply) get in the cell to activate TRPV1? To address this question, we used live-cell fluorescence imaging to monitor intracellular pH level on extracellular application of nicotinic acid, which would drop if nicotinic acid enters the cell and acidifies the cytoplasm. We observed that, with increasing concentrations of extracellular nicotinic acid (all titrated to pH 7.4), intracellular pH dropped exponentially over time in a concentration-dependent manner and plateaued at 6.63±0.02 (n=3) with 130 mmol/L nicotinic acid ( Figure 7B and 7C). The rate of intracellular pH reduction also increased exponentially when the nicotinic acid concentration was increased, reaching a saturated level of 64.4±6.3 s -1 (n=3) at room temperature when nicotinic acid concentration was higher than 60 mmol/L ( Figure 7D ). The fact that nicotinic acid translocation saturates at high concentrations points to a transporter-mediated mechanism, which is consistent with previous reports in intestinal epithelia cells 38, 39 and liver cells.
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Discussion
Nicotinic acid remains an underused therapy for dyslipidemias and cardiovascular disease because of the strong unwanted niacin flush side effect. Although nicotinic acid binds to HCA2, resulting in catabolism of arachidonic acid and release of prostaglandins, there are data suggesting that nicotinic acid may cause vasodilation by other mechanisms.
Results from the present study on knockout animal physiology, electrophysiology, and pharmacology, as well as live-cell fluorescence imaging, collectively demonstrate that nicotinic acid directly and potently activates TRPV1. The concentrations needed to elicit an effect are within the range attainable in patient plasma. 41 Our findings present a likely additional pathway for the niacin flushing response that substantially hinders the highly beneficial nicotinic acid treatment.
As a member of the B family vitamins, nicotinic acid at normal physiological concentrations regulates blood cholesterol and fat, in part, by interacting with HCA2 in adipocytes. Because under clinical settings the blood concentration of nicotinic acid is substantially raised, 41 unintended targets, such as the polymodal cellular sensor TRPV1, are activated. The noticeable low apparent binding affinity of nicotinic acid to TRPV1 is consistent with this view. Indeed, although TRPV1 in nerve terminals under the skin is thought to serve as a primary temperature sensor, it is also abundantly expressed in internal organs where temperature variation is minimal. It is thought that TRPV1 serves its physiological role in these organs as a nociceptor through activation induced by endogenous ligands or extracellular H + (eg, under inflammatory or ischemic conditions). 42 Nicotinic acid seems to be yet another chemical compound that TRPV1 can sense. The flushing response to nicotinic acid is a multicomponent complex biological event that, in blood flow profiles, is presented as a biphasic increase in dermal blood flow. 16 through a shift of the heat activation threshold. Although the voltage-dependent activation and ligand-dependent activation are also affected, it seems that these processes are not capable of independently bringing the activity of TRPV1 to a level sufficient to produce a physiological response. Nonetheless, it is possible that these processes may contribute to the physiological effects of nicotinic acid through a multiallosteric mechanism. 43 Further investigations under more physiological conditions are needed to elucidate the details on how nicotinic acid alters cellular physiology.
The emerging picture from the present study is as follows. When a patient undergoes treatment, the blood nicotinic acid concentration elevates significantly. Nicotinic acid is transported into Langerhans cells and keratinocytes by a transporter yet to be identified. Transporters for nicotinic acid have been functionally identified; however, their molecular identity remains unknown. [38] [39] [40] As has been previously proposed, the ubiquitous H + -coupled monocarboxylate transporters and Na + -coupled monocarboxylate transporters are interesting potential candidates underlying nicotinic acid transportation. 39, [44] [45] [46] Monocarboxylate transporters are known to transport L-lactate, pyruvate, the ketone bodies, and many other monocarboxylates across the plasma membrane. 47 Once entered into the cytosol, nicotinic acid binds to TRPV1 and causes the channel to be heat activated at physiological temperatures. Potentiation of ligand-and voltage-dependent activations may contribute to this process. The activation of TRPV1 leads to Ca 2+ influx into Langerhans cells and keratinocytes, causing downstream vasodilation and nerve sensation. Studies with Trpv1 -/-knockout mice suggested that missing the TRPV1 channel leads to vasoconstriction, 48 supporting the notion that upregulation of TRPV1 activity by nicotinic acid or other means may lead to vasodilation.
Conclusions
Identification of TRPV1 activation as a likely candidate mediating nicotinic acid-induced flushing side effects opens up new ways to improve patient compliance of this beneficial treatment. Indeed, because TRPV1 is a polymodal receptor, its activity can be regulated by numerous physical and chemical methods. The channel thus presents ample opportunities to reduce the flushing response.
